[Frontiers in Bioscience 14, 1793-1806, January 1, 2009]

[Frontiers in Bioscience 14, 1793-1806, January 1, 2009]

Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases

Ann Westman-Brinkmalm¹, Ulla Ruetschi², Erik Portelius¹, Ulf Andreasson¹, Gunnar Brinkmalm¹, Gosta Karlsson¹, Sara Hansson¹, Henrik Zetterberg¹, Kaj Blennow¹

1Institute of Neuroscience and Physiology, Department of Psychiatry and Neuochemistry, The Sahlgrenska Academy at Goteborg University, Sweden, ²Institute of Laboratory Medicine, Department of Clinical Chenistry and Transfusion Medicine, The Sahlgrenska Academy at Göteborg University, Sweden

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Methods
3.1. 2-DGE-MS
3.2. SELDI-TOFMS
3.3. IP-MS
4. Cerebrospinal fluid
5. Results: 5.1. Alzheimer's disease; 5.2. Frontotempral dementia; 5.3. Multiple sclerosis
6. Discussion and conclusions
7. Acknowledgement
8. References

1. ABSTRACT

Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.